SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-157250"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-157250" > Effects of Denosuma...

Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney Function

Jamal, Sophie A. (författare)
Ljunggren, Östen (författare)
Uppsala universitet,Institutionen för medicinska vetenskaper
Stehman-Breen, Catherine (författare)
visa fler...
Cummings, Steven Ron (författare)
McClung, Michael R. (författare)
Goemaere, Stefan (författare)
Ebeling, Peter R. (författare)
Franek, Edward (författare)
Yang, Yu-ching (författare)
Egbuna, Ogo I. (författare)
Boonen, Steven (författare)
Miller, Paul D. (författare)
visa färre...
 (creator_code:org_t)
2011
2011
Engelska.
Ingår i: Journal of Bone and Mineral Research. - 0884-0431 .- 1523-4681. ; 26:8, s. 1829-1835
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6Months (FREEDOM) Study. We estimated creatinine clearance (eGFR) using Cockcroft-Gault and classified levels of kidney function using the modified National Kidney Foundation classification of CKD. We examined incident fracture rates; changes in bone mineral density (BMD), serum calcium, and creatinine; and the incidence of adverse events after 36 months of follow-up in subjects receiving DMAb or placebo, stratified by level of kidney function. We used a subgroup interaction term to determine if there were differences in treatment effect by eGFR. Most (93%) women were white, and the mean age was 72.3 +/- 5.2 years; 73 women had an eGFR of 15 to 29mL/min; 2817, between 30 to 59mL/min; 4069, between 60 to 89mL/min, and 842 had an eGFR of 90mL/min or greater. None had stage 5 CKD. Fracture risk reduction and changes in BMD at all sites were in favor of DMAb. The test for treatment by subgroup interaction was not statistically significant, indicating that treatment efficacy did not differ by kidney function. Changes in creatinine and calcium and the incidence of adverse events were similar between groups and did not differ by level of kidney function. It is concluded that DMAb is effective at reducing fracture risk and is not associated with an increase in adverse events among patients with impaired kidney function.

Nyckelord

impaired kidney function
denosumab
fractures
bone mineral density
MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy